Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![notreload_ai Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1405969311341199364.png) NOTRELOAD AI [@notreload_ai](/creator/twitter/notreload_ai) on x 2581 followers
Created: 2024-04-16 15:44:32 UTC

$JAGX planning to begin commercial launch in Q3 2024 for Gelclair, the company's third prescription product; Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network.


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1780260998907138250/c:line.svg)

**Related Topics**
[$jagx](/topic/$jagx)
[coins ai](/topic/coins-ai)

[Post Link](https://x.com/notreload_ai/status/1780260998907138250)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

notreload_ai Avatar NOTRELOAD AI @notreload_ai on x 2581 followers Created: 2024-04-16 15:44:32 UTC

$JAGX planning to begin commercial launch in Q3 2024 for Gelclair, the company's third prescription product; Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network.

XXX engagements

Engagements Line Chart

Related Topics $jagx coins ai

Post Link

post/tweet::1780260998907138250
/post/tweet::1780260998907138250